Search results for "LOD"

showing 10 items of 4833 documents

Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring.

2007

To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists (ARB).Studies in which blood pressure (BP) was measured using ambulatory BP monitoring for at least 24 h were collected from MEDLINE. Data for each treatment group, ARB, placebo or the drug used for its comparison were obtained from the selected studies. Only studies with a minimum of quality criteria were selected. The final study group contained 36 publications, with a total of 47 patient cohorts receiving ARB in monotherapy, 10 with placebo, 10 with amlodipine, and five with enalapril. The reduction in clinical and ambulatory BP during 24 h, day, night and the last 4-h period fo…

Malemedicine.medical_specialtyAmbulatory blood pressurePhysiologyMEDLINEPharmacologyurologic and male genital diseasesEnalaprilInternal medicineInternal MedicinemedicineHumanscardiovascular diseasesAntihypertensive AgentsAngiotensin II receptor type 1Dose-Response Relationship Drugbusiness.industryEprosartanBlood Pressure Monitoring AmbulatoryAngiotensin IIfemale genital diseases and pregnancy complicationsEndocrinologyLosartanValsartanACE inhibitorHypertensionFemaleAmlodipineTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockershormones hormone substitutes and hormone antagonistsmedicine.drugJournal of hypertension
researchProduct

Long-term use of angiotensin II receptor antagonists and calcium-channel antagonists in Algerian hypertensive patients: Effects on metabolic and oxid…

2015

The effects of calcium antagonists (amlodipine) and angiotensin II receptor antagonists (telmisartan) on lipid profile and oxidative markers were investigated in Algerian hypertensive patients. At the beginning and after 1 year of antihypertensive therapy, blood samples are collected for determination of biochemical parameters (glucose, cholesterol, triglycerides, urea, creatinine) and oxidative markers (malondialdehyde, carbonyl proteins, nitric oxide, superoxide anion, vitamin C, glutathione, catalase, superoxide dismutase). The results of this study indicate that telmisartan and amlodipine are effective antihypertensive agents in the treatment of hypertension because a significant reduct…

Malemedicine.medical_specialtyAngiotensin receptorPharmacologymedicine.disease_causeBenzoatesBiochemistryAngiotensin Receptor Antagonistschemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineHumansTelmisartanAmlodipineAngiotensin Receptor Antagonistsmedicine.diagnostic_testChemistryMiddle AgedCalcium Channel BlockersMalondialdehydeOxidative StressEndocrinologyBlood pressureAlgeriaHypertensionBenzimidazolesFemaleAmlodipineTelmisartanLipid profileOxidative stressmedicine.drugFree Radical Biology and Medicine
researchProduct

Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Misse…

2016

Background Central aortic blood pressure (CBP) and CBP-derived parameters are independent predictors of cardiovascular risk. Angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors plus calcium channel blockers are the recommended first-line treatments in hypertensive diabetic patients; however, the effect in reducing CBP when a dose is skipped has not been established yet. The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine (OLM/AML) provides equal efficacy and safety as the perindopril/AML (PER/AML) combination in reducing CBP, augmentation index (AIx), and pulse wave velocity (PWV) when a drug dose is missed. Methods In this no…

Malemedicine.medical_specialtyMissed DoseFixed-dose combinationUrologyTetrazolesolmesartanPulse Wave Analysisamlodipine030204 cardiovascular system & hematologyNO03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal MedicinemedicinePerindoprilHumans030212 general & internal medicineAmlodipineamlodipine antihypertensive agents blood pressure diabetes mellitus olmesartan perindoprilPulse wave velocityAgedbusiness.industryImidazolesblood pressureMiddle Agedantihypertensive agentsBlood pressureDiabetes Mellitus Type 2Hypertensiondiabetes mellitusAortic pressureFemaleperindoprilOlmesartanbusinessmedicine.drugAmerican Journal of Hypertension
researchProduct

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

2009

Background Acquired somatic deletions and loss-of-function mutations in one or several codons of the TET2 ( Ten-Eleven Translocation-2 ) gene were recently identified in hematopoietic cells from patients with myeloid malignancies, including myeloproliferative disorders and myelodys-plastic syndromes. The present study was designed to determine the prevalence of TET2 gene alterations in chronic myelomonocytic leukemias. Design and Methods Blood and bone marrow cells were collected from 88 patients with chronic phase chronic myelomonocytic leukemia and from 14 with acute transformation of a previously identified disease. Polymerase chain reaction analysis and direct sequencing were used to se…

Malemedicine.medical_specialtyMyeloidDNA Mutational AnalysisChronic myelomonocytic leukemiaSingle-nucleotide polymorphismKaplan-Meier EstimateGene mutationBiologymedicine.disease_causeDioxygenasesGene FrequencyMonocytosisInternal medicinehemic and lymphatic diseasesProto-Oncogene ProteinsmedicineHumansGenetic Predisposition to DiseaseLetters to the EditorAgedProportional Hazards ModelsAged 80 and overComparative Genomic HybridizationMutationHematologyLeukemia Myelomonocytic ChronicHematologyMiddle Agedmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesDNA-Binding ProteinsLeukemiamedicine.anatomical_structureImmunologyMutationFemaleOriginal Article
researchProduct

Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project

2010

AbstractChanging definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health Organization classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66 371 lymphoid malignancies (LMs) and 21 796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100 000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.6…

Malemedicine.medical_specialtyPathologyChildhood leukemiaHematologic malignant; Europe; morphologic subtype; international comparison; population-based cancer registry.ImmunologyPopulationUNITED-STATESALCOHOLBiochemistryNOMyelodysplastic–myeloproliferative diseasesInternal medicineEpidemiologymorphologymedicineLYMPHOMAHumansEPIDEMIOLOGYRegistriesEXPOSUREeducationRISKeducation.field_of_studyTOBACCOhaematologic malignanciesbusiness.industryIncidence (epidemiology)IncidenceleukemiaMyeloid leukemiaCell BiologyHematologyHematologic malignancies; morphology; Europe.Plasma cell neoplasmmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesLymphomaEuropeCANCER INCIDENCEHematologic Neoplasmscancer incidence tobacco alcohol epidemiology leukemia risk exposureCHILDHOOD LEUKEMIAHematologic malignanciesFemalebusiness
researchProduct

Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics an…

2020

Background: Different studies have indicated that thiazide diuretics can increase the risk of developing type 2 diabetes (T2D). Therefore, in this study, we investigated whether switching from hydrochlorothiazide (HCTZ) to amlodipine resulted in ameliorating different cardiovascular and metabolic measures in hypertensive patients with or without T2D. Methods: This study [Diuretics and Diabetes Control (DiaDiC)] was a 6-week, single-blind, single-center randomized controlled trial. The first 20 normal glucose-tolerant, 20 prediabetic, and 20 T2D consecutive patients were randomized to continue the previous antihypertensive treatment with HCTZ (12.5-25 mg/day) or to switch from HCTZ to amlodi…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismSodium Chloride Symporter InhibitorsdiureticBlood PressureType 2 diabetesSettore MED/13 - EndocrinologiaInternal medicineInternal MedicineMedicineHumansSingle-Blind MethodAmlodipineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateThiazideAntihypertensive AgentsAgedtreatmentbusiness.industryDrug Substitutioncardiovascularfood and beveragesMiddle Agedmedicine.diseaseCalcium Channel BlockersDiabetes controlHydrochlorothiazideTreatment OutcomeDiabetes Mellitus Type 2ItalyHypertensionCardiologyFemaletype 2 diabetesAmlodipinethiazidebusinessEnergy MetabolismmetabolismBiomarkersmedicine.drugMetabolic syndrome and related disorders
researchProduct

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent…

2015

Summary Background Acute myeloid leukaemia mainly affects elderly people, with a median age at diagnosis of around 70 years. Although about 50–60% of patients enter first complete remission upon intensive induction chemotherapy, relapse remains high and overall outcomes are disappointing. Therefore, effective post-remission therapy is urgently needed. Although often no post-remission therapy is given to elderly patients, it might include chemotherapy or allogeneic haemopoietic stem cell transplantation (HSCT) following reduced-intensity conditioning. We aimed to assess the comparative value of allogeneic HSCT with other approaches, including no post-remission therapy, in patients with acute…

Malemedicine.medical_specialtyTransplantation ConditioningGemtuzumab ozogamicinmedicine.medical_treatmentAntibodies Monoclonal HumanizedCOUNCIL AML11 TRIALEUROPEAN LEUKEMIANETInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointINDUCTION CHEMOTHERAPYHumansTransplantation HomologousProspective StudiesADULT PATIENTS610 Medicine & healthBusulfanMETAANALYSISAgedMYELODYSPLASTIC SYNDROMEChemotherapyRISK-ADAPTED APPROACHbusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInduction chemotherapyHematology1ST COMPLETE REMISSIONTotal body irradiationMiddle AgedGemtuzumabGEMTUZUMAB OZOGAMICINSurgeryFludarabineTransplantationSurvival RateLeukemia Myeloid AcuteAminoglycosidesTreatment OutcomeSURVIVALFemaleNeoplasm Recurrence LocalbusinessBusulfanVidarabinemedicine.drugLancet. Haematology
researchProduct

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study

2016

Rüdiger Sauer,1 Michaela Hänsel,2 Roland Buhl,3 Roman A Rubin,4 Marcel Frey,5 Thomas Glaab2,3 1Lung Centre Ulm, Ulm, Germany; 2Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 3Pulmonary Department, Mainz University Hospital, Mainz, Germany; 4Pulmonary Specialist Practice, Wiesbaden, Germany; 5Biometrics, Alcedis GmbH, Gießen, Germany Background: Maintaining and improving physical functioning is key to mitigating the cycle of deconditioning associated with chronic obstructive pulmonary disease (COPD). We evaluated the impact of free combination of the long-acting anticholinergic tiotropium plus the long-acting β2-agonist ol…

Malereal-worldTime FactorsnoninterventionalHealth StatusSeverity of Illness IndexCholinergic AntagonistsPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicinetiotropiumDeconditioningPhysical functioningSurveys and QuestionnairesProspective Studies030212 general & internal medicineLungOriginal ResearchCOPDOlodaterolGeneral MedicineTiotropium bromideMiddle AgedBronchodilator AgentsDrug CombinationsTreatment OutcomeFemalemedicine.drugmedicine.medical_specialtymedicine.drug_classInternational Journal of Chronic Obstructive Pulmonary Diseasechronic obstructive pulmonary disease03 medical and health sciencesAdministration InhalationSeverity of illnessmedicineAnticholinergicphysical functioningHumansTiotropium BromideIntensive care medicineAdrenergic beta-2 Receptor AgonistsAgedolodaterolbusiness.industryNebulizers and VaporizersRecovery of Functionmedicine.diseaseBenzoxazines030228 respiratory systemchemistryPhysical therapyObservational studybusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Pētera Šmita vēstule Jānim Misiņam par sēdi Rīgas Latviešu biedrības Zinību komisijā

1926

Atklātnē īsa informācija par Manharda lietu, kas novilcinās, vēsturnieku biedrību, Rīgas Latviešu biedrības Zinību komisijas sēdi 1926. gada 8. oktobrī ar F. Baloža priekšlasījumu par Latvijas arheoloģiju.

Mannhardt Wilhelm (1831-1880):HUMANITIES and RELIGION [Research Subject Categories]Šmits PēterisRīgas Latviešu biedrības Zinību komisijaMisiņš JānisBalodis Francisarheoloģija
researchProduct

Five new species of Marantaceae endemic to Gabon

2012

ABSTRACT Five new species of African Marantaceae are described and illustrated from two locations in Gabon, Marantochloa alba A. C. Ley, sp. nov., M. grandiflora A. C. Ley, sp. nov., M. montsdecristalii A. C. Ley, sp. nov. and Thaumatococcus flavus A. C. Ley, sp. nov. from the mountainous area of Monts de Cristal, north east of the capital Libreville, as well as Hypselodelphys lopei A. C. Ley, sp. nov. from the central part of Gabon in secondary forest near La Lope and Mikongo. New keys to the genera Marantochloa Brongn. & Gris., Thaumatococcus Benth. and Hypselodelphys (K. Schum.) Milne.-Redh. are provided.

MarantaceaeMarantochloaLiliopsidaZingiberalesPlant ScienceNorth eastBiodiversityBiologybiology.organism_classificationThaumatococcusTracheophytaMarantaceaeHypselodelphysBotanySecondary forestPlantaeTaxonomy
researchProduct